natgillin/translations-raw huggingface dataset:
The anti-CD20 antibody formulation for use according to Claim 1, wherein the sodium acetate is present in an amount of about 50mM. 
Formulacija protutijela an4-CID20 za uporabu prema zahtjevu 1, naznačena time, da je natrijev acetat prisutan u količini od 50 mM.
For administration to man in the curative or prophylatic treatment of cardiac conditions and hypertension, oral dosages of the compounds will be in the range of from 2-50 mg daily for an average adult patient (70 kg). 
Za davanje ljudima u kurativnom ili profilaktičkom tretiranju srčanih stanja i hipertenzije, oralne doze spoja bit će u opsegu od 2-50 mg dnevno za prosječnog odraslog pacijenta (70 kg).
contacting the trans-(-)-A9-tetrahydrocannabinol from step (b) with trans-(+)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition; or by 
kontaktiranje trans-(-)-A9-tetrahidrokanabinola iz koraka (b) sa trans-(+)-A9-tetrahidrokanabinolom i nepolarnim organskim otapalom tako da formiraju prvi sastav;
the at least one active immunogenic component comprises live attenuated canine adenovirus type 2 (CAV2) and live attenuated canine parvovirus (CPV) or 
(b) najmanje jedna aktivna imunogena komponenta sadrži živi atenuirani adenovirus pasa tipa 2 (CAV2) i živi atenuirani parvovirus pasa (CPV) ili
the casing further comprises a tubular portion matching and extending from the opening of the main surface. 
- < kućište poželjno nadalje sadrži cjevasti dio koji odgovara otvoru glavne površine i od njega se proteže.
In some embodiments, the process is characterized by at least one of the following features (1)-(3). 
Postupak prema patentnom zahtjevu 52, naznačen najmanje jednom od slijedećih karakteristika (1)-(3):
Such isomers, polymorphs, and solvates may be prepared by methods known in the art, such as by regiospecific and/or enantioselective synthesis and resolution. 
Takvi izomeri, polimorfi i solvati mogu se pripraviti metodama poznatim u struci, kao što su regiospecifična i/ili enantioselektivna sinteza i rezolucija.
A method according to claim 19, wherein the disease treated is Hodgkins disease. A method according to claim 19, wherein the disease treated is selected from the group consisting of solid tumors selected from the group consisting of tumors of the breast, bladder, bone, brain, central nervous system, peripheral nervous system, colon, endocrine glands, thyroid, adrenal cortex, esophagus, endometrium, germ cells, head and neck, liver, lung, larynx, hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, small intestine, soft tissue, testis, stomach, skin, ureter, vagina, Retinoblastoma, Wilms tumor, and secondary tumors in distant organs, 
Upotreba u skladu s patentnim zahtjevom 17, naznačena time što se zloćudne novotvorine bira između čvrstih tumora, hematoloških tumora, te nasljednih oblika raka, uključujući tumore dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, uključujući štitnjaču 1 koru nadbubrežne žlijezde, jednjaka, endometrija, germinativnih stanica, glave 1 vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekih tkiva, testisa, želuca, kože, uretera, vagine i vulve, retinoblastom i Wilmsov tumor, agresivne i indolentne oblike leukemije 1 limfoma, neHodgkinovu bolest, kroničnu i akutnu mijeloidnu leukemiju (CML/AML), akutnu limfoblastičnu leukemiju (ALL), Hodgkinovu bolest, multipli mijelom, T-stanični limfom, mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastične sindrome, rak nepoznatog primarnog sijela i malignome povezane s AIDS-om.
A method of obtaining an oil as claimed in claim 1, which comprises 
Postupak dobivanja ulja sukladno zahtjevu 1, koji sadrži
A method of treating a disease or condition that is nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence, or a bleeding disorder, the method comprising administering a solid form according to claim 3 to a patient in need thereof. 
Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V> receptorima izabrano između noćnog mokrenja, nokturije, poliurije uslijed centralnog dijabetesa insipidusa, urinarne inkontinencije 1 poremećaja krvarenja.
The immunogenic composition of paragraph 62 wherein the additional antigens are antigens derived from a bacterium selected from the group consisting of S.pneumoniae, H.influenzae, N.meningitidis, E.coli, M.cattarhalis, tetanus, diphtheria, pertussis, S.epidermidis, enterococci, and S.aureus. 
Imunogeni pripravak u skladu s patentnim zahtjevom 26, naznačen time što su dodatni antigeni antigeni dobiveni iz bakterije koju se bira iz skupine koju čine 5. pneumoniae, H. influenzae, N.meningitidis, E. coli, M. cattarhalis, tetanus, difterija, hripavac, S. epidermidis, enterokoki, S.aureus i Pseudomonas aeruginosa.
The method of claim 6, wherein the compound of formula (X) is obtained by homologation of a compound of formula (IX): and optionally wherein the homologation is achieved in the presence of dichloromethane and n-butyllithium. 
[image] te se opcionalno pritom, premještanje kloro skupine postiže u prisutnosti litijevog bis(trimetilsilil)amida. Postupak prema patentnom zahtjevu 5, naznačen time, da se spoj formule (X) dobiva pomoću homologiranja spoja formule (IX):
providing a drawer being mounted in a furniture body and capable of being pulled out from said body, and 
- < pripremanje ladice koja je montirana u tijelu namještaja i koja se može izvući iz navedenog tijela, 1
is a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl; 
je izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C1-C8) alkila, (C3-C8) cikloalkila, heterociklila, arila i heteroarila;
The method of item 1, wherein the filler is selected from the group consisting of corn starch, potato starch, wheat starch, rice starch, partial alpha starch, alpha starch, lactose hydrate, fructose, glucose, mannitol, anhydrous dibasic calcium phosphate, crystalline cellulose, and precipitate calcium carbonate. 
Postupak prema zahtjevu 1, naznačen time što punilo odabrano iz skupine koja se sastoji od kukuruznog škroba, krumpirovog škroba, pšeničnog škroba, rižinog škroba, parcijalnog alfa škroba, alfa škroba, laktoza hidrata, fruktoze, glukoze, manitola, bezvodnog dvobaznog kalcijevog fosfata, kristalne celuloze, i taložnog kalcijevog karbonata.
The process of claims 14, wherein the vacuum condition is less than an absolute pressure measured in millibar (mbar) selected from the group consisting of 950, 900, 850, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50, 30, 20, 10, 5, and 0.5 mBar. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što su vakuumski uvjeti manji od apsolutnog tlaka izmjerenog u milibarima (mbar), koji se bira iz skupine koju čine 950, 900, 850, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50, 30, 20, 10, 5 1 0,5 mbar.
According to the invention, the raw materials have to show a minimum content, measured as gaschromatographic purity, higher than 50% and, in general, equal to the assay required for the finished compound. 
Prema izumu, sirovi materijali moraju pokazati minimalni sadržaj, mjereno kao plinsko-kromatografska čistoća, veći od 50 % i, općenito, jednak udjelu potrebnom za završni spoj.
Preference is given to using glass beads made of soda-lime glass, soda-lime-silica glass or borosilicate glass. 
Pripravci prema bilo kojem od zahtjeva 1 do 9, naznačeni time da se kao komponenta B) koriste staklene kuglice izrađene od natron-vapno stakla, natron-vapno-silikatnog stakla ili borosilikatnog stakla.
A compound, or pharmaceutically acceptable salt thereof, chosen from: 
Spoj ili farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, izabrano od:
ring A is independently selected from phenyl substituted with 0-1 R6 and 0-2 R7; and 
Spoj u skladu sa patentnim zahtjevom 1, gdje: prsten A je nezavisno odabran od:
Universal indicator pH 0-14—Merck. 
- < Univerzalni indikator pH 0-14 - Merck.
A process for the preparation of a compound of formula VIII 
ii u svrhu dobivanja spoja formule IV' he 8"
Step 4: Removal of the protecting group 
Broj objave europskog patenta:
The stable aqueous aldehyde solution according to claim 1 wherein the aldehyde comprises at least one component selected from the group consisting of: formaldehyde, acetaldehyde, proprionaldehyde, butraldehyde, pentanaldehyde, hexanaldehyde, heptanaldehyde, octanaldehyde, nonanaldehyde, glutaraldehyde, succinaldehyde, ethane dialdehyde, 2-ethyl hexanaldehyde, iso-valeraldehyde, chloraldehyde hydrate, furfuraldehyde, paraformaldehyde. 
Stabilna vodena otopina aldehida u skladu s patentnim zahtjevom 1 pri čemu aldehid obuhvaća barem jedno od sljedećeg: formaldehid, acetaldehid, propionaldehid, glutaraldehid, butiraldehid, pentanaldehid, heksanaldehid, heptanaldehid, oktanaldehid, nonanaldehid, sukcinaldehid, glioksal, 2-etil_heksanaldehid, izo-valeraldehid, kloraldehid hidrat, furfuraldehid, paraformaldehid.
is hydrogen, together with R9 a double bond or together with R9 an epoxy group -O-; 
R'' je vodik, zajedno s R? je dvostruka veza ili zajedno s R? je epoksi skupina -O-;
If two wall elements 2 are positioned next to each other, in an abutting relationship, there is formed a recess having three sides of 200 mm, which is intended for accommodating the columns, as is shown in Fig. 1. As the steel or wooden columns 1 will not exactly have these dimensions, they are provided with inserts 5 which are placed against the particular columns 1 in order to substantially fill the recess between the wall elements 2. 
Ako su dva zidna elementa 2 postavljena jedan do drugoga, tako da se upiru, oblikuje se udubljenje koje ima tri stranice od 200 mm, koje je namijenjeno da se u njega smjeste stupovi, kako je prikazano slikom 1, Kako čelični ili drveni stupovi neće imati točno ove dimenzije, uz njih su predvideni umetci 5 koji se postavljaju uz odredene stupove 1 kako bi dovoljno ispunili udubljenja među zidnim elementima 2.
The recombinant Mycobacterium bovis cell of claim 1, wherein the recombinant Mycobacterium bovis cell does not carry an antibiotic resistance gene. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1, naznačena time što rekombinantna Mycobacterium bovis stanica ne nosi gen za rezistenciju na antibiotike.
Use according to claim 5, 7 and 8 wherein the gastro-enteritis is caused by infection of a rotavirus of at least three non-G1 serotypes selected from the group consisting of G2, G3, G4 and G9. 
Upotreba u skladu s patentnim zahtjevom 5, 7 1 8, naznačena time što gastroenteritis je uzrokovan infekcijom od strane najmanje tri serotipa rotavirusa koji nisu G1 i biraju se iz skupine koju čine G2, G3, G4 1 G9.
The method according to claim 1, wherein the TNF-a-related disease is one or more selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, systemic scleroderma, localized scleroderma, Sjogren's syndrome, polymyositis, dermatomyositis, ulcerative colitis, Crohn's disease, Behcet's disease, multiple sclerosis, arteriosclerosis, myasthenia gravis, ankylosing spondylitis, diabetes, arteriosclerosis, sepsis, acute infectious diseases, asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, contact dermatitis, psoriasis, acne, osteoporosis, burns, the onset of rejection associated with organs or tissue transplantation, fever, anemia, cancer, periodontal disease, glaucoma, diabetic complications, and uveitis. The method according to claim 1, wherein the TNF-a-related disease is a skin disease. 
Farmaceutski pripravak prema patentnom zahtjevu 11 za upotrebu u prevenciji ili liječenju bolesti povezanih s TNF-a, naznačen time da je bolest povezana s TNF-a jedna ili više bolest iz grupe bolesti koja uključuje reumatoidni artritis, posorijatični artritis, sistemski eritemski lupus (SLE), lupus nefritis, sistemsku skelodermiju, lokalnu skelodermiju, Sjorgenov sindrom, polimiozitis, dermatomiozitis, ulcerativni kolitis, Kronovu bolest, Behcetovu bolest, multiplu sklerozu, arteriosklerozu, mijasteniju gravis, ankilozantni spondilitis, dijabetis, arteriosklerozu, sepsu, akutnu infekciju, astmu, kroničnu opstruktivnu bolest pluća (COPD), atopijski dermatitis, kontaktni dermatitis, psorijazu, akne, osteosporozu, opekline, napad ili odbacivanje povezano s transplantacijom organa ili tkiva, vrućicu, anemiju, rak, paradontozu, glaukom, dijabetičke komplikacije i uveitis.
Further compounds, like liothyronine sodium, lactose and/or maize starch and/or microcrystalline cellulose, can be also included. 
Također mogu biti uključeni dodatni spojevi, kao natrij liotironin, laktoza i/ili kukuruzni škrob i/ili mikrokristalinična celuloza.
The polyalkylene oxide-adenosine deaminase conjugate of claim 7, wherein the polyethylene glycol has a molecular weight of from 4,000 to 45,000. 
Konjugat adenozin deaminaze i polialkilen oksida u skladu s patentnim zahtjevom 7, naznačen time, da polietilen glikol ima molekulsku masu od 4.000 do 45.000.
the polysaccharide chains are essentially free of chemically intact non-sulfated iduronic and/or glucuronic acids from the pentasaccharide sequences mediating the anticoagulant effect; and 
(vV) polisaharidni lanci su u osnovi bez kemijski intaktnih ne-sulfatnih iduronskih i/ili glukuronskih kiselina iz pentasaharidnih sekvenci koje posreduju u efektu antikoagulacije; i
The sole for shoes according to claim 11, characterized in that said vapor-permeable plugs (220a, 220b, 220c, 220d, 220e, 320) are provided by means of one or more of the following materials: sintered granular powders, aluminum foams, porous and vapor-permeable plastic materials, ceramic materials, compressed synthetic or natural fibers, leather, and salpa. 
Potplat za cipele u skladu s patentnim zahtjevom 11, naznačen time, da su navedeni paropropusni čepovi (220a, 220b, 2206, 220d, 2206, 320) izrađeni od jednog ili više sljedećih materijala: sinterirani granularni prahovi, aluminijske pjene, porozni i paropropusni plastični materijali, keramički materijali, stlačena sintetska ili prirodna vlakna, koža i salpa.
The base station device sets RA-RNTI (Random Access-Radio Network Temporary Identity), representing that a random access response to the mobile station device transmitting the random access preamble via the random access channel is set to the downlink shared channel (PDSCH), to the downlink control channel (PDCCH). 
Uređaj mobilne stanice (50) prema zahtjevu 1 ili 2, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena koja je uključena u primljenom odgovoru slučajnog pristupa (S02).
and, R3 is selected from the group consisting of H, —OH, —NH2. 
je izabran iz grupe koja se sastoji od H, -OH, -NH2.
A is is independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, NRCRD, and (NRCRD)carbonyl; 
je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena hidroksi, hidroksialkila, NRCRD i (NRCRD)karbonila; n je 0, 1, 2 ili 3;
Use of a compound or composition according to any of claims 1 to 19 or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof in the manufacture of a medicament for the treatment of cancer. 
Upotreba spojeva ili smijese prema bilo kojem od zahtjeva 1 do 19, ili farmaceutski prihvatljive soli, tautomera ili stereoizomera istoga, naznačena time, što se koristi za izradu lijeka za liječenje kancera.
The ODT for use according to claim 14, wherein said inflammatory condition of the gastrointestinal tract comprises inflammation of the esophagus, eosinophilic esophagitis, or inflammation of the glottis, epiglottis, tonsils, or oropharynx. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 16, naznačeno time da navedena upala gastrointestinalnog trakta obuhvaća upalu jednjaka, eozinofilni ezofagitis, ili upalu glotisa, epiglotisa, tonzila ili orofarinksa.
The SDS and IL-2 in the microaggregates interact non-covalently, and the hydrophobic tail of IL-2 (residues 121-133) may interact with the alkyl backbone of SDS to form the micelles. 
SDS i IL-2 u mikroagregatima međusobno djeluju nekovalentno, i hidrofobni završetak od TL-2 (ostaci 121-133) mogu međusobno djelovati s alkilnim kosturom SDS da oblikuju micele.
A human engineered antibody or antigen-binding fragment thereof, according to claim 1 or a pharmaceutical composition according to claim 2, for use in therapy. 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time što je namijenjen upotrebi u terapiji.
A modified serpin according to any one of claims 1 to 7 wherein the mutations in the RCL of the modified serpin consist of mutations at positions P1' and P2; positions P1', P2 and P1; positions P1', P2 and P4; or positions P1', P2, P4 and P1. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se mutacije u RCL-petlji od modificiranog serpina, sastoje od mutacija na pozicijama P1' i P2; pozicijama P1', P2 i P1; pozicijama P1', P2 i P4; ili pozicijama P1', P2, P4 1 P1.
The method according to any one of claims 3 to 9 further comprising adding a fermentation co-factor to the milk source. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što se dodatno sastoji u dodavanju fermentacijskog kofaktora izvoru mlijeka.
(MRCoNS), vancomycin-intermediate or vancomycin--resistant Staphylococcus aureus (VISA, VRSA), mupirocin-resistant Staphylococcus sp., vancomycin-resistant Enterococcus sp. 
(MRCoNS), vankomicin-intermedijarni ili vankomicin-rezistentnim Staphilococcus aureus (VISA, VRSA), mupirocin-rezistentnim Staphilococcus sp., vankomicin-rezistentnim Enterococcus sp.
Harvested cysts according to claim 18, wherein said magnetic particles comprise an oxide of one or more transition metals or a ferrite. 
Ciste prema zahtjevu 7, naznačene time što magnetske čestice sadrže feromagnetski, ferimagnetski ili paramagnetski materijal, magnetske čestice sadrže poželjno oksid jednog ili više prijelaznih metala, posebno F&0;
A monoclonal antibody which is produced by a hybridoma ILT7#11 deposited under Accession number FERM BP-10704 or a hybridoma ILT7#17 deposited under Accession number FERM BP-10705, or a fragment comprising its antigen binding region. 
HR P20130494 T1 PATENTNI ZAHTJEVI Monoklonalno antitijelo koje se veže na vanstaničnu domenu humanog ILT7 ili fragment koji sadrži regiju koja ga veže na antigen, naznačeno time da to monoklonalno antitijelo sadrži nizove amino kiselina u skladu s bilo kojim od niže navedenoga pod 1) do ili) kao CDR1, CDR2 i CDR3, u njihovoj varijabilnoj regiji teškog lanca i varijabilnoj Tegiji lakog lanca: i) CDRI varijabilne regije teškog lanca: SDYAWN (ID br.
The PAL variant of claim 6, wherein the variant is made by reacting AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of the AvPAL variant. 
AvPAL varijanta u skladu s patentnim zahtjevom 5, naznačena time, da se može dobiti reakcijom AvPAL varijante s polietilen glikolom aktiviranim NHS-om u omjeru 3 polietilenglikola po ostatku lizina AvPAL varijante.
Another aspect of the disclosure is a metabolite of the compound or the pharmaceutical composition according to any one of paragraphs [0033]-[0138]. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak želudca.
The rotary drive action of the motor 12 is converted into a linear relative movement of the two jaw members 6, 7. 
Djelovanje rotacijskog pogona elektromotora 12 se pretvara u odgovarajuće linearno kretanje dvaju elemenata čeljusti 6, 7.
The pharmaceutical dosage formulation of claim 8, wherein the glidant is selected from the group consisting of talc, cornstarch, and silica. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je glidant izabran iz grupe koju čine talk, kukuruzni škrob 1 silika.
subjects having a serum cholesterol level of at least 200 mg/dL [240 mg/dL]; 
(ii) subjekti koji imaju razinu kolesterola u serumu od barem 200 mg/dI;
a proximal collar fitting (3) with coupling halves at each of two separate ends, said distal end of said single push-pull-turn hose (5) adapted for being connected in a releasable way to the proximal collar fitting (3), 
- < proksimalnu spojnicu (3) s polovicama spojnice na svakom od dva nasuprotna kraja, pri čemu je distalni kraj spomenutog crijeva za potiskivanje-povlačenje-okretanje (5) izveden na način da se spaja na proksimalnu spojnicu (3) tako da se može otpustiti
The use of the system according to any of the preceding claims, wherein the water activity reducing agent of the first composition constitutes at least 60 percent by weight of the composition, such as at least 70 percent by weight of the composition, at least 80 percent by weight of the composition at least 85 percent by weight of the composition, at least 90 percent by weight of the composition, at least 92 percent by weight of the composition, at least 95 percent by weight of the composition, at least 98 percent by weight of the composition 
Upotreba sustava u skladu sa bilo kojim prethodnim zahtjevom, naznačena time, što aktivitet vode redukcijskog sredstva prvog sastava čini najmanje 60 posto po masi sastava, kao što je barem 70 posto po masi sastava, najmanje 80 posto po masi sastava, barem 85 posto po masi sastava, najmanje 90 posto po masi sastava, najmanje 92 posto po masi sastava, najmanje 95 posto po masi sastava, najmanje 98 posto po masi sastava.
Process for the preparation of the composition according to any one of claims 1 to 12 comprising mixing and processing donepezil hydrochloride and excipients to the desired composition. 
Postupak pripreme pripravka prema bilo kojem od patentnih zahtjeva 1 do 12 koji se sastoji od miješanja i prerade donepezil hidroklorida sa ekscipijensima, čime se dobiva željeni pripravak.
loading a beverage container (14) into the pressure chamber (4), 
- < umetanje spremnika pića (14) u tlačnu komoru (4),
A monoclonal antibody or antigen-binding fragment thereof that binds human CGRP receptor, wherein the monoclonal antibody or antigen-binding fragment thereof selectively inhibits the human CGRP receptor as compared with human AM1, AM2, and AMY1 receptors with a selectivity ratio of 100 or more as determined by a cAMP inhibition assay. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema patentnom zahtjevu 1, naznačeno time što monoklonsko protutijelo ili njegov antigen-vezujući fragment selektivno inhibira ljudski CGRP receptor u usporedbi s ljudskim AMI, AM2, i AMY1 receptorima s omjerom selektivnosti od 100 ili više kao što je određeno s testom inhibicije CAMP.
the composition contains SDS/IL-2 aggregates with a mean hydrodynamic diameter of between 8 nm and 20 nm; and/or 
(ii) sastav sadrži SDS/IL-2 agregate sa srednjim hidrodinamičkim promjerom između 8 nm i 20 nm;
purifying the salt of the compound of formula (V) by crystallization in the presence of an acid to form the neutral form of the compound of formula (V). 
Cc) - pročišćavanje soli spoja s formulom (V), kristalizacijom soli spoja s formulom (V) u organskom otapalu ili smjesi organskog otapala i vode u prisutnosti kiseline, da se dobije neutralni oblik spoja s formulom (V).
Preferably, the present compounds of formula (Ia) or (Ib) are combined with rifapentin and moxifloxacin. 
PATENTNI ZAHTJEVI L Spoj prema općoj Formuli (la) ili općoj Formuli (Ib)
contacting the amplified nucleic acid of (a) with a detectable nucleic acid probe specific for the SNP of the virulent strain of MDV-1; 
stavljanju u kontakt amplificirane nukleinske kiseline iz koraka (a) s detektabilnom nukleinskokiselinskom sondom specifičnom za SNP virulentnog soja MDV-1;